





**Supplementary Figure 1.** SDS-PAGE gel showing the purification of B31 DBPA. Lanes 1 and 3 contain the before induction samples while lanes 2 and 4 show the production of Ubi-B31 after induction. Lane 5 shows the flow-through from the first  $\text{Ni}^{2+}$  column. Purification with a second  $\text{Ni}^{2+}$  column after digestion resulted in the purified protein (Lane 6) and elution fractions containing undigested B31 and ubiquitin (Lanes 7 and 8).




**Supplementary Figure 2.** Reducing end TEMPO labeling of heparin fragments through reductive amination.




**Supplementary Figure 3.** Gel mobility shift assay of heparin dp6 in the presence of increasing concentrations of (A) B31 WT,  $^{64}\text{SDSS}^{67}$ ,  $^{176}\text{SSS}^{178}$ , and  $^{187}\text{SCS}^{189}$  and of (B) B31 WT,  $^{64}\text{SDSS}^{67}$ , and K82,170S.




**Supplementary Figure 4.** Gel mobility shift assay of DS dp6 in the absence and in the presence of B31 WT, <sup>64</sup>SDSS<sup>67</sup>, K82,170S, <sup>176</sup>SSS<sup>178</sup>, and <sup>187</sup>SCS<sup>189</sup>.



**Supplementary Figure 5.**  $K_D$  curves of two residues for each B31 wildtype and mutants. These residues (A54, E186, and N191) experienced the greatest linear peak migration when titrated with heparin dp6, and these peaks were analyzed to give the  $K_D$  for each B31 variant. Residue A54 was used in place of E186 for the K82,170S mutant due to poor signal-to-noise from E186 of the mutant.




**Supplementary Figure 6.** ITC data for DBPA (A) B31 WT, (B)  $^{64}\text{SDSS}^{67}$ , and (C) K82,170S. The  $K_D$ s from this data show the same trend quantified by NMR.



**Supplementary Figure 7.** Transverse <sup>1</sup>H magnetization relaxation curves and HSQCs of residues N59 and F60 in the presence of oxidized (black) and reduced (red) radical. The maximum intensities have been normalized to 1.

B31	----MIKCNNKTFNNLLKLTLILVNLLISCGLTGATKIRLERSAKDITDEIDAIIKKDAALK	56
297	----MIKCNNKTFNNLLKLTLILVNLLISCGLTGATKIKLESSAKAIVDEIDAIIKKKAASM	56
N40	MNKYQKTFKIFNFKNLLKLSLLV-ALISCGLKGETKIIILERSAKDITDEINKIKKDAADN	59
PBr	-----MIKYNNKILLKLSLIVSLLVACGLTGETKIRLESSAQEIKDEINKIKANAKKE	52
VS461	-----MIKYNNKIILTLLASLLAACSLTGK--ARLESSVKDITNEIDKAIAKAACDA	50
	: : *.*::: . * : *.*. * ** *.: * : **: *	
B31 57	GVNFDAFKDKKTGSGVSENP-FILEAKVRATTVAEKFVIAIEEEATKLKETGS-SGEFSA	114
297 57	GVNFDAFKDKKTGSGVSENP-FILEAKVRATTVAEKFVIAIEEEATKLKETGS-SGEFSA	114
N40 60	NVNFAAFTDSETGSKVSENS-FILEAKVRATTVAEKFVTAEIGEATKLKKTGS-SGEFSA	117
PBr 53	GVKFEAFTNTQTGSKISEKPEFILKAKIKAIQVAERFVKAIKEEAELKKSGS-SGAFSA	111
VS461 51	GVNTDAFTETQTGGKVAGSQ--IRDAAKKLVADLTIEFLKATEEETITFKENGAGEDEFSG	108
	*: **.: :**. :: . * .** : : .*: * : * : . :*: . **.	
B31 115	MYDLMFEVSKPLQQLGIQEMTKTVSDAAEENPPTTAQGVLEIAKKMREKLQRVHTKNYCT	174
297 115	MYDLMFEVSKPLQELGIQEMTKTVSMAAEENPPTTAQGVLEIAKKMREKLQRVHKKNQDT	174
N40 118	MYNMMLEVSGPLEELGVLRMTKTVTDAAEQHPTTAEGILEIAKIMKTKLQRVHTKNYCA	177
PBr 112	MYDLMIDVSKPLEEIGIQKMTGTVKEAAQKTPATTADGIIIAIAQAMEDKLNNVNKKQHDA	171
VS461 109	IYDLYRTAEAVEKIGMK-VKQAVEDTAKENPKTTANGIIIAIVKVMKAKVENIKEKQTKN	167
	:*: .: . :*: : . :* :*: * ***: : *.: *. *: . *: . *:	
B31 175	LKKKENSTFTDEKCKNN 191	
297 175	LKKKNTEDSTAKS--- 187	
N40 178	LEKKKNPNFTDEKCKNN 194	
PBr 172	LKNLKEKAKTATT--- 185	
VS461 168	QK----- 169	
	*	

**Supplementary Figure 8.** Sequence alignment of DBPA variants found in B31, 297, N40, PBr and VS461 strains for Borrelia. Strain B356 is not shown because it has 99 % sequence identity with strain N40.



**Supplementary Figure 9.** K<sub>D</sub> curves of N-terminal residues T28 and T101 of wildtype B31.